Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer

Trials

Volumn 9, Issue , 2008, Pages

  Aydiner, Adnan ^a   Tas, Faruk ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; DATA BASE; DISEASE FREE SURVIVAL; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; MONOTHERAPY; POSTMENOPAUSE; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 49249116168     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-9-47     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 2005, 365:1687-717. 10.1016/S0140-6736(05)66544-0 15894097
2. Dorssers LC Flier Van der S Brinkman A van Agthoven T Veldscholte J Berns EM Klijn JG Beex LV Foekens JA Tamoxifen resistance in breast cancer: Elucidating mechanisms Drugs 2001, 61:1721-33. 10.2165/ 00003495-200161120-00004 11693462
3. Gradishar WJ Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women Oncology 2005, 69:1-9. 10.1159/000087282 16088229
4. Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group Forbes JF Cuzick J Buzdar A Howell A Tobias JS Baum M Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 2008, 9:45-53. 10.1016/S1470-2045(07)70385-6 18083636
5. Baum M Budzar AU Cuzick J Forbes J Houghton JH Klijn JG Sahmoud T Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial Lancet 2002, 359:2131-9. 10.1016/S0140-6736(02)09088-8 12090977
6. Jakesz R Jonat W Gnant M Mittlboeck M Greil R Tausch C Hilfrich J Kwasny W Menzel C Samonigg H Seifert M Gademann G Kaufmann M Wolfgang J ABCSG and the GABG Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 2005, 366:455-62. 10.1016/S0140-6736(05)67059-6 16084253
7. Boccardo F Rubagotti A Puntoni M Guglielmini P Amoroso D Fini A Paladini G Mesiti M Romeo D Rinaldini M Scali S Porpiglia M Benedetto C Restuccia N Buzzi F Franchi R Massidda B Distante V Amadori D Sismondi P Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial J Clin Oncol 2005, 23:5138-47. 10.1200/JCO.2005.04.120 16009955
8. Boccardo F Rubagotti A Guglielmini P Fini A Paladini G Mesiti M Rinaldini M Scali S Porpiglia M Benedetto C Restuccia N Buzzi F Franchi R Massidda B Distante V Amadori D Sismondi P Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial Ann Oncol 2006, 17(Suppl 7):vIi10-4. 10.1093/annonc/mdl941 16760270
9. Baum M Buzdar A Cuzick J Forbes J Houghton J Howell A Sahmoud T The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 2003, 98:1802-10. 10.1002/cncr.11745 14584060
10. Winer EP Hudis C Burstein HJ Wolff AC Pritchard KI Ingle JN Chlebowski RT Gelber R Edge SB Gralow J Cobleigh MA Mamounas EP Goldstein LJ Whelan TJ Powles TJ Bryant J Perkins C Perotti J Braun S Langer AS Browman GP Somerfield MR American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 2005, 23:619-29. 10.1200/JCO.2005.09.121 15545664
11. Jonat W Gnant M Boccardo F Kaufmann M Rubagotti A Zuna I Greenwood M Jakesz R Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis Lancet Oncol 2006, 7:991-6. 10.1016/ S1470-2045(06)70948-2 17138220
12. Jakesz R The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8 28th Annual SABCS; 2005.
13. Kaufmann M Jonat W Hilfrich J Eidtmann H Gademann G Zuna I von Minckwitz G Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study J Clin Oncol 2007, 25:2664-70. 10.1200/JCO.2006.08.8054 17563395
14. Mauri D Pavlidis N Polyzos NP Ioannidis JP Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis J Natl Cancer Inst 2006, 98:1285-91. 16985247
15. Gibson LJ Dawson CK Lawrence DH Bliss JM Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women Cochrane Database Syst Rev 2007:CD003370. 17253488
16. Moher D Cook DJ Eastwood S Olkin I Rennie D Stroup DF Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses Lancet 1999, 354:1896-900. 10.1016/S0140-6736(99)04149-5 10584742
17. Normand SL Meta-analysis: Formulating, evaluating, combining, and reporting Stat Med 1999, 18:321-59. 10.1002/ (SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P 10070677
18. Boccardo F Rubagotti A Aldrighetti D Buzzi F Cruciani G Farris A Mustacchi G Porpiglia M Schieppati G Sismondi P Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: Pooled analysis of 2 consecutive trials Cancer 2007, 109:1060-7. 10.1002/cncr.22513 17295293
19. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 CA Cancer J Clin 2005, 55:74-108. 15761078
20. Ingle JN Adjuvant endocrine therapy for postmenopausal women with early breast cancer Clin Cancer Res 2006, 12:1031s-1036s. 10.1158/ 1078-0432.CCR-05-2122 16467121
21. Mouridsen HT Robert NJ The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women Eur J Cancer 2005, 41:1678-89. 10.1016/j.ejca.2004.10.020 16098456
22. Morandi P Rouzier R Altundag K Buzdar AU Theriault RL Hortobagyi G The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: The M. D. Anderson Cancer Center evidence-based approach Cancer 2004, 101:1482-9. 10.1002/cncr.20522 15378476
23. Henderson IC Piccart-Gebhart MJ The evolving role of aromatase inhibitors in adjuvant breast cancer therapy Clin Breast Cancer 2005, 6:206-15. 16137430
24. Goss PE Emerging role of aromatase inhibitors in the adjuvant setting Am J Clin Oncol 2003, 26:S27-33. 10.1097/00000421-200308001-00005 12902874
25. Buzdar A Chlebowski R Cuzick J Duffy S Forbes J Jonat W Ravdin P Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer Curr Med Res Opin 2006, 22:1575-85. 10.1185/030079906X120940 16870082
26. Buzdar A Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial Clin Breast Cancer 2003, 4(Suppl 1):S42-8. 12756078
27. Jakesz R Samonigg H Greil R Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a) Proc Am Soc Clin 2005, 23:aBstract 527.
28. Cuzick J Sasieni P Howell A Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006, 94:460-4. 10.1038/sj.bjc.6602964 16434989
29. Buzdar AU Cuzick J Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data Clin Cancer Res 2006, 12:1037s-1048s. 10.1158/1078-0432.CCR-05-2458 16467122
30. Burstein H Winer E Kuntz K Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors [abstract 529] J Clin Oncol (Meeting Reports) 2005, 23:11.
31. Hilsenbeck SG Osborne CK Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial Clin Cancer Res 2006, 12:1049s-1055s. 10.1158/ 1078-0432.CCR-05-2123 16467123